These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 27209210

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA.
    Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA, Sabaa BE, Abdelkhalik D, Mansour H, Melis M, Shaalan W, Farouk M, Malik E, Soliman AA.
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [Abstract] [Full Text] [Related]

  • 6. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.
    BMC Cancer; 2015 Jul 01; 15():492. PubMed ID: 26122176
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C, He L, Wei Q, Li Q, Jiang L, Zhao L, Wang C, Li J, Wei M.
    Cancer Med; 2020 Feb 01; 9(3):1242-1253. PubMed ID: 31856408
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S.
    Drug Resist Updat; 2016 Jan 01; 24():55-69. PubMed ID: 26830315
    [Abstract] [Full Text] [Related]

  • 11. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    Zhang G, Zhang J, Zhu Y, Liu H, Shi Y, Mi K, Li M, Zhao Q, Huang Z, Huang J.
    Exp Cell Res; 2021 Sep 01; 406(1):112742. PubMed ID: 34302857
    [Abstract] [Full Text] [Related]

  • 12. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
    Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B.
    Hum Pathol; 2013 May 01; 44(5):777-85. PubMed ID: 23114921
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.
    Am J Obstet Gynecol; 2013 Jul 01; 209(1):62.e1-9. PubMed ID: 23583215
    [Abstract] [Full Text] [Related]

  • 15. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, Cárdenas S, Silva-Ayala R, Almaraz M, Méndez C.
    J Ovarian Res; 2016 Jul 07; 9(1):41. PubMed ID: 27388275
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R.
    Anticancer Res; 2014 Jan 07; 34(1):393-9. PubMed ID: 24403493
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
    Beussel S, Hasenburg A, Bogatyreva L, Hauschke D, Werner M, Lassmann S.
    J Clin Pathol; 2012 Jan 07; 65(1):29-35. PubMed ID: 22011448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.